![Hui Tian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hui Tian
Private Equity Investor bei
The Column Group LLC
Profil
Dr. Hui Tian joined The Column Group in 2022 as a Venture Partner.
Previously he was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research.
In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer.
In a span of 14 years, he led the discovery and advancement of more than a dozen clinical candidates.
Prior to NGM, he was a Scientific Director at Amgen and Tularik leading discovery research in the areas of metabolic disorders and orphan G protein-coupled receptors.
Dr. Tian received a Ph.D.
in Molecular and Cellular Biology at the University of Texas Southwestern Medical Center and did his post-doctoral training at Harvard University.
Aktive Positionen von Hui Tian
| Unternehmen | Position | Beginn |
|---|---|---|
The Column Group LLC
 The Column Group LLC Investment ManagersFinance TCG invests in companies located in the United States. The firm focuses on drug discovery, biology, chemistry, and technology sectors. It provides financing for early and later stage capital requirements with an investment size of USD 50 - 60 million. | Private Equity Investor | 01.03.2022 |
Ehemalige bekannte Positionen von Hui Tian
| Unternehmen | Position | Ende |
|---|---|---|
| NGM BIOPHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.05.2022 |
| AMGEN INC. | Corporate Officer/Principal | 31.12.2008 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in cancer and inflammatory disease treatments | Corporate Officer/Principal | 31.12.2004 |
Ausbildung von Hui Tian
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
88
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in cancer and inflammatory disease treatments | Commercial Services |
NGM Biopharmaceuticals, Inc.
 NGM Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel & life-changing medicines | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Column Group LLC
The Column Group LLC Investment ManagersFinance TCG invests in companies located in the United States. The firm focuses on drug discovery, biology, chemistry, and technology sectors. It provides financing for early and later stage capital requirements with an investment size of USD 50 - 60 million. | Finance |
The University of Texas Southwestern Medical Center
 The University of Texas Southwestern Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
